We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Faron Pharmaceuticals OY (FARN) NPV

Sell:120.00p Buy:130.00p 0 Change: No change
FTSE AIM 100:0.09%
Market closed Prices as at close on 27 February 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:120.00p
Buy:130.00p
Change: No change
Market closed Prices as at close on 27 February 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:120.00p
Buy:130.00p
Change: No change
Market closed Prices as at close on 27 February 2024 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Faron Pharmaceuticals Oy is a Finland-based clinical stage biopharmaceutical company. The company has three drug candidates all based on mastering immune modulation and, as a result, tackling unmet needs in cancer, preventing organ damage and treating blood count abnormalities. The Company's goal is to build future immunotherapy, i.e., to bring new treatments to patients by affecting the immune system. Faron’s drug candidate, Traumakine, is a drug developed by the Company to prevent multi-organ damage and excessive inflammatory responses. Another drug candidate, Haematokine, promotes the expansion of bone marrow stem cells. It is being developed, e.g., for the treatment of chemotherapyinduced neutropenia (CIN). In neutropenia patients have less blood cells called neutrophils than normal due to cancer treatment.

Contact details

Address:
Joukahaisenkatu 6
TURKU
20520
Finland
Telephone:
+358 (02) 4695151
Website:
https://www.faron.com/

Important dates

Future events
Final results 29 February 2024 29/02/24
Annual report 29 February 2024 29/02/24
Past events
EGM 22 September 2023 22/09/23
Interim results 29 August 2023 29/08/23
Interim results 30 June 2023 30/06/23
AGM 24 March 2023 24/03/23
Annual report 03 March 2023 03/03/23
Final results 03 March 2023 03/03/23
Final results 02 March 2023 02/03/23

General stock information

EPIC:
FARN
ISIN:
FI4000153309
Market cap:
£86.01 million
Shares in issue:
68.81 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
FTSE AIM 100,FTSE AIM All Share

Key personnel

  • Markku Jalkanen
    Chief Executive Officer, Executive Director
  • James O'Brien
    Chief Financial Officer
  • Juho Jalkanen
    Chief Operating Officer
  • Maija Hollmen
    Chief Scientific Officer
  • Birge Berns
    Interim Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.